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Abstract
Background:  To apply clarithromycin as an immunomodulatory treatment in experimental
urosepsis by multidrug-resistant Pseudomonas aeruginosa.
Methods: Acute pyelonephritis was induced in 40 rabbits after inoculation of the test isolate in
the renal pelvis. Therapy was administered upon signs of sepsis in four groups: A, controls; B,
intravenous clarithromycin; C, amikacin; and D, both agents. Survival and vital signs were recorded;
blood was sampled for culture and estimation of pro-inflammatory mediators; monocytes were
isolated for determination of apoptotic rate and ex vivo TNFα secretion. Quantitative cultures and
biopsies of organs were performed after death.
Results: Increased rectal temperature and oxygen saturation were found in groups B and D
compared to A and C. Mean survival of groups A, B, C and D was 2.65, 7.15, 4.25 and 8.70 days
respectively. No differences were noted between groups concerning bacterial load in blood and
tissues and serum endotoxins. Serum MDA and total caspase-3 activity of monocytes of group D
decreased following treatment compared to other groups. Negative correlation was detected
between cytoplasmic caspase-3 and ex vivo secretion of TNFα of blood monocytes of group A;
similar correlation was not found for any other group. Pathology scores of liver and lung of group
B were lower than group A.
Conclusion: Clarithromycin administered late in experimental urosepsis by multidrug-resistant P.
aeruginosa prolonged survival and ameliorated clinical findings. Its effect is probably attributed to
immunomodulatory intervention on blood monocytes.
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Background
Thorough search for the evolution of methods of immu-
nointervention in sepsis is based on animal models of
pre-treatment. In these models therapy is administered
before induction of sepsis; as a consequence their findings
signify the importance of the administered compound to
inhibit triggering of the inflammatory cascade [1]. On the
contrary, in clinical practice, patients are admitted to hos-
pitals due to sepsis resulting from a full-blown inflamma-
tory cascade; in these patients immunomodulators have
failed probably because they were not potent enough to
inhibit an inflammatory cascade that had already been
initiated [2]. Intravenous clarithromycin has already been
applied as pre-treatment in experimental pyelonephrits by
multidrug-resistant  Pseudomonas aeruginosa leading to
prolonged survival and attenuation of the systemic
inflammatory response [3]. The effect of clarithromycin
was attributed to the elaboration of serum concentrations
close to 10 µg/ml, where nuclear factor-κB (NF-κB), the
transcription factor of pro-inflammatory cytokines, is
inhibited [4].
The present study attempted to simulate clinical practice;
therefore clarithromycin was administered upon presen-
tation of clinical signs of urosepsis in an experimental ani-
mal model. Aims of the study were: a) the effect of
clarithromycin on overall survival; b) its probable synergy
with amikacin, and; c) its effect on blood monocytes.
Methods
Bacterial isolate
One blood isolate of P. aeruginosa derived from a female
patient with acute pyelonephritis and severe sepsis was
applied. Minimal inhibitory concentrations (MICs) of
ticarcillin/clavulanate, piperacillin, ceftazidime, imi-
penem, meropenem, ciprofloxacin, clarithromycin and
amikacin determined by a microdilution technique were
equal to >256/2, >512, 16, 64, 32, >512, 128 and 256 mg/
L respectively; the isolate was considered multidrug-resist-
ant [5].
The isolate was stored as multiple aliquots in skim milk
(Oxoid Ltd, London, UK) at -70°C. Before each experi-
ment, one aliquot was thawed and cultured onto McCo-
nkey agar plates (Becton Dickinson, Cockeysville Md).
Single colonies were suspended in Mueller-Hinton broth
(Oxoid) and incubated for 12 hours at 37°C in a shaking
water bath. The resulting inoculum was washed three
times with NaCl 0.9% to remove any free endotoxins.
Animals
A total of 40 white New Zealand male rabbits of a mean
(± SD) weight of 3.19 ± 0.30 kg were applied. The study
received permit from the Veterinary Directorate of the Per-
fecture of Athens according to the Greek legislation in
conformance to the 160/1991 Council Directive of the
EU. Animals were housed in single metal cages and had
access to tap water and standard balanced rabbit chow ad
libitum. Room temperature ranged between 18 and 22°C,
relative humidity between 55 and 65% and the light/dark
cycle was 6 am/6 pm.
Study design
Acute pyelonephritis was induced by a modification of
the protocol, described by others [3,6]. Animals were ini-
tially sedated by the intramuscular injection of 25 mg/kg
of ketamine and 5 mg/kg of xylazine. Anesthesia was
maintained by the intramuscular administration of 15
mg/kg of xylazine at 30-minute time intervals. Through an
upper midline abdominal incision, the peritoneal cavity
was entered and the intestines were displaced to the left.
The right ureter was recognized and ligated with a 3.0
suture just below the pelvis. A total of 1 × 107 cfu of the
pathogen, at a volume of 0.1 ml, were injected by a 26-
Gauge needle into the renal pelvis, proximal to the suture.
The peritoneal cavity and the abdominal wall were closed
in layers.
Vital signs of the animals were recorded at 30-minute time
intervals; oxygen saturation by an electrode attached to
the left ear (Electronic for Medicine); and body tempera-
ture by a thermometer placed in the rectum (Omron, Ber-
lin, Germany). One ml of blood was sampled by puncture
of the vein of their left ear and collected into EDTA-coated
tubes (Vacutainer, Becton Dickinson) before and 1.5
hours after bacterial challenge. White blood cell counts
were estimated by a standard analyzer. Hypothermia,
decrease of oxygen saturation and leukopenia were noted
within 1.5 hours after bacterial challenge (see below).
These signs were indicative of the advent of sepsis [7], so
as to allow for that time interval to be considered as ade-
quate for the administration of treatment.
Animals were then divided into four study groups as fol-
lows:
- Group A (n: 10); controls administered 30 ml of normal
saline intravenously.
- Group B (n: 10); animals administered two doses of clar-
ithromycin. It was provided as a pyrogen-free amorphous
powder (Abbott, Chicago, USA). After reconstitution with
10 ml of 5% glucose, appropriate amounts were added
into NaCl 0.9% at a final volume of 30 ml that was
infused by a pump within 30 minutes. The first dose,
equal to 80 mg/kg, was administered 1.5 hours after bac-
terial challenge; the second dose, equal to 30 mg/kg, 3.5
hours after bacterial challenge. Each dose was infused
within 30 minutes, in analogy to former studies [3].BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
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- Group C (n: 10); animals administered intravenous
bolus 8 mg/kg of amikacin, two hours after bacterial chal-
lenge, as proposed elsewhere [8].
- Group D (n: 10); animals administered both clarithro-
mycin and amikacin; the first dose of clarithromycin was
followed by amikacin.
A volume of 3 ml of blood was sampled from the vein of
the left ear of each animal before the operation, and at 1.5,
3.5, 24 and 48 hours and collected into pyrogen-free tubes
(Vacutainer, Becton Dickinson). After centrifugation,
serum was kept refrigerated at -70°C until assayed for
endotoxins (LPS), tumor necrosis factor-alpha (TNFα),
malondialdehyde (MDA) and drug levels. At 3.5, 24 and
48 hours one more ml of blood was collected into
heparin-coated syringes for the isolation of monocytes.
Survival of animals was recorded each 12 hours for a total
period of follow-up of 21 days. After death autopsy was
performed; animals remaining alive after 21 days of fol-
low-up were sacrificed by the intravenous administration
of sodium thiopental. Under sterile conditions, segments
from the right kidney, liver, spleen and lower lobe of the
right lung were taken and placed into separate sterile plas-
tic containers for quantitative cultures and biopsy.
Assays for LPS, TNFα and MDA
For the estimation of LPS, serum samples were diluted
1:10 in sterile and pyrogen-free water (BioWhitaker,
Walkersville, Maryland, USA) and incubated for five min-
utes at 70°C. The concentration of LPS was then measured
by the QCL-1000 Limulus Amoebocyte Lysate assay (Bio-
Whitaker, lower limit of detection 1 EU/ml) using a stand-
ard curve created by known concentrations of LPS by
Escherichia coli serotype O111:B4. All determinations were
performed in duplicate and the mean of two observations
was applied.
TNFα was measured by a bioassay on L929 fibrosarcoma
cell line, as already described [3,9]. Briefly, confluent cells
were thoroughly washed with Hank' s solution and har-
vested with 0.25% thrypsin/0.02% EDTA (Biochrom AG,
Berlin, Germany). Cells were centrifuged, re-suspended in
RMPI 1640 supplemented with 10% Fetal Bovine Serum
and 2 mM of glutamine (Biochrom AG) and distributed
into a 96-well cell culture plate at a density of 1 × 105 cells/
well. The final volume of fluid into each well was 0.05 ml.
After incubation for 2–3 hours at 37°C at 5% CO2, 0.06
ml of serum or of standard dilutions of known concentra-
tions of human TNFα (Sigma, range 5.75–375.00 pg/ml)
were added into each well followed by 0.05 ml of a 0.3
mg/ml dilution of cycloheximide (Sigma). Incubation
continued over-night; then the supernatant of each well
was discarded by aspiration and 0.1 ml of a 0.5 mg/ml
methylene blue solution in methanol 99% was added.
After ten minutes, the dye was removed and wells were
thoroughly washed three times with 0.9% sodium chlo-
ride. Wells were left to dry and remnants of the dye in each
well became soluble by the addition of 0.1 ml of 50% gla-
cial acetic acid (Merck, Darmstadt, Germany). Optical
density in each well was read at 495 nm (Hitachi Specto-
photometer, Tokyo, Japan) against blank wells and con-
trol wells without added serum. Concentrations of TNFα
were estimated by the reduction of the optical density of
Comparative values of oxygen saturation and rectal tempera- ture of animals with acute pyelonephritis by multidrug-resist- ant Pseudomonas aeruginosa Figure 1
Comparative values of oxygen saturation and rectal tempera-
ture of animals with acute pyelonephritis by multidrug-resist-
ant Pseudomonas aeruginosa. A: controls, B: clarithromycin, C: 
amikacin, D: both agents. Therapy was started 1.5 hours after 
bacterial challenge; asterisks denote statistical differences 
compared to group A.BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
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control wells by unknown samples applying a standard
curve generated by standard concentrations. All determi-
nations were performed in quadruplicate. The inter-day
variation of the assay was 13.75%.
Lipid peroxidation was estimated by the concentration of
MDA, as already described [10]. Briefly, a 0.1 ml aliquot
of each sample was mixed to 0.9 ml of trichloroacetic acid
20% (Merck) and centrifuged at 12,000 g and 4°C for 10
minutes. The supernatant was removed and incubated
with 2 ml of thiobarbituric acid 0.2% (Merck) for 60 min-
utes at 90°C. After centrifugation, a volume of 10 µl of the
supernatant was injected into a high-performance liquid
chromatography system (HPLC, Agilent 1100 Series,
Waldbronn, Germany) with the following characteristics
of elution: Zorbax Eclipse XDB-C18 (4.6 × 150 mm, 5
µm) column under 37°C; mobile phase consisting by a 50
mM K3PO4 (pH: 6.8) buffer and methanol 99% at a 60/40
ratio with a flow rate of 1 ml/min; fluorometric detection
with signals of excitation at 515 nm and emission at 535
nm. The retention time of MDA was 3.5 minutes and it
was estimated as µmol/l by a standard curve created with
1, 1, 3, 3-tetramethoxy-propane (Merck). All determina-
tions were performed in duplicate. The total oxidant sta-
tus of each animal was assessed by the area under the
MDA versus time curve; it was calculated by the linear
trapezoidal rule and expressed in µmol.h/l.
Blood and tissue cultures
Volumes of 0.5 ml of blood were added into glass tubes
with two ml of thioglycolate medium (Becton Dickin-
son). A 0.1 ml aliquot was then diluted 1:10 into sterile
sodium chloride four consecutive times. Another aliquot
of 0.1 ml of each dilution was plated onto McConkey agar
and incubated at 35°C for a total period of three days.
Plates were incubated at 35°C and the number of viable
colonies were counted into each dilution and multiplied
by the appropriate dilution factor. The lower detection
limit was 50 cfu/ml. Bacterial cells in blood were
expressed by their log10 value.
Tissue segments were weighted and homogenized; a 0.1
ml aliquot was diluted, plated and incubated as described
for blood samples. Identification of colonies was per-
formed by the API20E system (bioMérieux, Paris, France).
The number of viable cells was expressed as its log10 value
in cfu/g. The lower detection limit was 10 cfu/g
Assay for blood monocytes
For the isolation of blood monocytes, heparinized venous
blood was layered over Ficoll Hypaque (Biochrom, Berlin,
Germany) and centrifuged. The separated mononuclear
cells were washed three times with PBS (pH 7.2) and re-
suspended in RPMI 1640 supplemented with 10% FBS
and 2 mM of glutamine in the presence of 100 U/ml of
penicillin G and 0.1 mg/ml of streptomycin (Sigma). After
incubation for 1 hour at 37°C in 5% CO2, non-adherent
cells were removed while adherent monocytes were
washed three times with Hank' s solution. Cells were then
harvested by 0.25% trypsin/0.02% EDTA and counted.
Half of them were treated with an ice-cold cell lysis buffer
(50 mM HEPES, 0.1% CHAPS, 5 mM DTT, 0.1 mM EDTA,
pH 7.4). After centrifugation for ten minutes at 10,000 g
under 4°C, activity of caspase-3 was estimated in the
cytosolic extract by an enzymatic chromogenic assay
(BIOMOL Research Laboratories, Plymouth, PA). It was
based on the rate of hydrolysis at 37°C of a substrate
releasing p-nitroaniline over-time, as assessed by sequen-
tial photometry at 410 nm. The assay was also performed
in the presence of a caspase-3 inhibitor. The activity of cas-
pase-3 in cell extracts was expressed as pmol/min.104
cells. The total caspase-3 activity of monocytes of each ani-
mal was assessed by the area under the caspase-3 versus
time curve; it was calculated by the linear trapezoidal rule
and expressed in pmol/104 cells.
The remaining half of monocytes were added into 12-well
plates at a volume of 2.4 ml per well with RPMI 1640 sup-
Comparative survival of animals with acute pyelonephritis by  multidrug-resistant Pseudomonas aeruginosa and administra- tion of therapy upon presentation of signs of sepsis Figure 2
Comparative survival of animals with acute pyelonephritis by 
multidrug-resistant Pseudomonas aeruginosa and administra-
tion of therapy upon presentation of signs of sepsis. A: con-
trols, B: clarithromycin, C: amikacin, D: both agents. p of 
comparisons between groups: A vs D 0.049; C vs D 0.045; A 
vs C NS (non-significant); and A vs B NSBMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
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plemented with 10% FBS and 2 mM of glutamine. They
were incubated for 18 hours at 37°C under 5% CO2.
TNFα of supernatants was estimated, as described above,
and expressed in pg/104 cells.
Pharmacokinetic analysis
Concentrations of clarithromycin in serum samples were
estimated by a modification of the method described else-
where [11]. Briefly, 0.1 ml of serum were mixed with 0.1
ml of a saturated dilution of NaCO3 and 1 ml of isopropa-
nol (Merck) and stirred for 15 minutes at 400 rpm. The
supernatant was centrifuged for 5 minutes at 2,700 g and
the organic layer was evaporated. The remaining was dis-
solved in 0.1 ml of acetonitrile and incubated for 40 min-
utes at 40°C with 0.1 ml of a K3PO4 buffer (100 mM, pH
6.8) and 0.1 ml of a 2.5 mg/ml dilution of FMOC (9-flu-
orenylmethyloxycarbonyl chloride, Sigma) in ace-
tonitrile. A volume of 50 µl was then injected into an
HPLC system with the following characteristics of elution:
Nucleosil 100-5 C18 (4.0 × 250 mm, 5 µm) column under
37°C; mobile phase consisting by a 50 mM K3PO4 (pH:
4.0) buffer and acetonitrile at a 60/40 ratio with a flow
rate of 1 ml/min; ultraviolet detection at 210 nm. One
standard curve of known concentrations was applied with
erythromycin as an internal standard. The lower detection
limit was 0.19 mg/l.
Concentrations of amikacin were estimated by a micro-
biological assay with Escherichia coli ICB4004 as a refer-
ence strain. Concentrations were estimated after designing
a standard curve with known concentrations into semilog-
arithmic climax. The lower detection limit was 0.7 mg/l.
Tissue pathology
Tissue segments were fixed with formalin, sliced appropri-
ately, embedded in paraffin and stained with hematoxylin
and eosin. A semi-quantitative scoring system was used
where segments of liver, kidney and lung were separately
scored for acute and chronic inflammation. Both acute
inflammation, characterized by infiltration by neu-
trophils, and chronic inflammation characterized by the
presence of mononuclear cells were scored as 0 (absent),
1 (sparse), 2 (moderate) and 3 (high). Segments of spleen
were separately scored for the enlargement of B- and T-
lymphocyte areas (0: absent, 1: slight, 2: moderate, and 3:
pronounced) and for the presence of germinal centers (0:
Table 1: Comparative concentrations of bacteria on blood, endotoxins (LPS), malondialdehyde (MDA) and tumor necrosis factor-
alpha (TNFα) of groups of treatment. Therapy was administered 1.5 hours after bacterial challenge.
Time (hours) after 
bacterial challenge
A (controls) B (clarithromycin) C (amikacin) D (clarithromycin + 
amikacin)
Bacteria in blood (Mean ± SE, log10 cfu/ml)
1.5 1.72 ± 0.31 2.53 ± 0.61 1.92 ± 0.23 2.00 ± 0.75
3.5 1.95 ± 0.26 2.05 ± 0.36 2.22 ± 0.36 1.20 ± 0.20
24 3.35 ± 1.23 4.91 ± 0.99 6.24 ± 0.76 3.72 ± 0.89
48 5.93 ± 1.06 5.94 ± 1.06 5.23 ± 1.77 5.13 ± 0.93
LPS (Mean ± SE, EU/ml)
1.5 10.79 ± 7.28 4.53 ± 1.94 10.15 ± 6.87 5.88 ± 2.68
3.5 1.17 ± 0.54 6.25 ± 2.94a 10.02 ± 6.72 3.92 ± 0.73
24 7.35 ± 2.02 11.09 ± 4.87 9.88 ± 3.72 36.22 ± 5.52
48 21.86 ± 16.42 3.00 ± 1.24 4.81 ± 2.79 8.11 ± 6.97
MDA (Mean ± SE, µmol/l)
0 2.56 ± 0.26 3.02 ± 0.88 2.18 ± 0.78 1.50 ± 0.39
1.5 2.52 ± 1.05 4.57 ± 1.33 3.48 ± 1.48 1.87 ± 0.52
3.5 3.19 ± 1.06 4.54 ± 1.26 2.09 ± 1.22 1.29 ± 0.26
24 3.74 ± 1.00 1.71 ± 0.73b 2.72 ± 2.24 1.89 ± 0.53
48 1.75 ± 0.53 3.13 ± 1.44 3.86 ± 2.79 4.77 ± 3.68
TNFα (Mean ± SE, pg/ml)
0 18.91 ± 4.95 21.98 ± 8.04 21.99 ± 4.71 22.50 ± 9.09
1.5 34.53 ± 15.55 11.57 ± 0.08 40.96 ± 23.29 113.67 ± 55.52
3.5 43.72 ± 27.02 17.33 ± 5.82 643.85 ± 609.53 31.77 ± 20.51
24 20.81 ± 11.71 248.82 ± 226.51 29.46 ± 17.96 60.49 ± 50.65
48 977,62 ± 97,63 32.81 ± 13.23 18.11 ± 6.61 47.53 ± 26.46
P of comparisons to group A: a0.042, b0.032BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
Page 6 of 10
(page number not for citation purposes)
absent, 1: presence). One single value was applied for
each organ segment after addition of separate scores (low-
est value: 0; highest value: 6).
Statistical analysis
Results were expressed by their mean (± SE). Comparisons
between groups were performed by Mann Whitney; values
were adjusted according to Bonferroni to avoid any ran-
dom correlation. Comparisons concerning tissue bacterial
load and pathology scores involved only those animals
that died. Survival was estimated by Kaplan-Meier analy-
sis; groups were compared by log-rank test.
Correlation between monocyte caspase-3 activity and ex
vivo production of TNFα by monocytes, as well as
between organ bacterial load and pathology scores were
performed according to Spearman.
Any value of p below 0.05 was considered as significant.
Results
Comparative curves of rectal temperature and oxygen sat-
uration over-time of groups of treatment are shown in Fig-
ure 1. Mean (± SE) of white blood cells of all animals
before operation were 9,230.0 ± 565.0/µl. At 1.5 hours
after bacterial challenge they were 6,157.5 ± 684.6/µl,
5,740.0 ± 618.1/µl, 5,500.0 ± 817.3/µl and 6,142.8 ±
468.5/µl for groups A, B, C and D respectively.
Over the 21-day follow-up, death occurred in all animals
of group A (mortality 100%); in eight animals of group B
(mortality 80%); in all animals of group C (mortality
100%); and in seven animals of group D (mortality 70%).
Mean (± SE) survival of animals of group A was 2.65 ±
0.57 days, of group B 7.15 ± 2.36 days, of group C 4.25 ±
1.89 days and of group D 8.70 ± 2.57 days. Survival curves
of all groups of treatment are shown in Figure 2. Statisti-
cally significant differences were found between groups A
and D (p: 0.049), between groups C and D (p: 0.045) but
not between groups A and C neither between groups A
and B.
Concentrations of bacteria in blood, LPS, MDA and TNFα
detected in serum over follow-up of groups A, B, C and D
are given in Table 1. Total oxidant status of groups A, B, C
and D as assessed by the area under the MDA versus time
curve were 161.89 ± 28.88, 119.51 ± 18.41, 135.87 ±
44.22 and 101.21 ± 37.64 µmol.h/l respectively. Signifi-
cant differences were found only between groups A and D
(p: 0.021).
The cytoplasmic activity of caspase-3 of blood monocytes
and the ex vivo release of TNFα by blood monocytes of
each group is given in Table 2. The total caspase-3 activi-
ties of monocytes of groups A, B, C and D as assessed by
the area under the caspase-3 versus time curve were
15,350.5 ± 9,234.5, 13,388.3 ± 11,252.7, 1,015.9 ± 536.8
and 473.7 ± 175.8 pmol/104 cells respectively. Significant
differences were found only between groups A and D (p:
0.048). A negative correlation was detected between cas-
pase-3 activity and ex vivo release of TNFα of monocytes
of group A (r: -0.466, p: 0.044). A lack of significance was
noted regarding the respective correlation in groups B (r:
+0.344, pNS), C (r: -0.179, pNS) and D (r: -0.080, pNS).
Bacterial loads and pathology scores of the infected kid-
ney, liver, spleen and lower lobe of the right lung when
death occurred are shown in Table 3 and in Figure 3. Neg-
ative correlations were found between bacterial load and
pathology scores of spleen of group B (r: -0.884, p: 0.047).
Mean log10of viable bacteria of liver, spleen, kidney and
lower lobe of the right lung of the two animals of group B
that eventually survived were 1, 1, 2.73 and 1 respectively.
Respective values for the three animals of group D that
eventually survived were 1.62, 1, 2.78 and 1.97. Mean
pathology scores of liver, spleen, kidney and lower lobe of
Table 2: Comparative rate of apoptosis and biosynthetic activity of blood monocytes of four animal groups with acute pyelonephritis 
by multidrug-resistant Pseudomonas aeruginosa. Rate of apoptosis was expressed by the activity of cytoplasmic caspase-3; biosynthetic 
activity by the ex vivo release of tumor necrosis factor-alpha (TNFα). Therapy was administered 1.5 hours after bacterial challenge.
Time (hours) after 
bacterial challenge
A (controls) B (clarithromycin) C (amikacin) D (clarithromycin + 
amikacin)
Cytoplasmic activity of caspase-3 (Mean ± SE, pmol/min.104 cells)
3.5 1810.2 ± 1779.6 3210.3 ± 1173.5 277.5 ± 273.0 1155.7 ± 647.8
24 2187.0 ± 1205.9 1096.6 ± 431.9 663.7 ± 662.2 647.9 ± 453.1
48 1129.5 ± 863.3 908.1 ± 908.1 6575.5 ± 657.8 112.3 ± 80.6
Ex vivo release of TNFα (Mean ± SE, pg/104 cells)
3.5 96.6 ± 61.9 394.6 ± 315.5 132.2 ± 44.3 342.7 ± 259.9
24 60.5 ± 39.9 34.5 ± 15.8 143.3 ± 126.5 10.6 ± 3.9a
48 63.1 ± 25.1 15.9 ± 10.6b 79.4 ± 68.4 71.7 ± 19.1
P of comparisons to group A: a0.016, b0.049BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
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the right lung of the two animals of group B that eventu-
ally survived were 0.5, 0, 1.5 and 0 respectively. Respective
values for the three animals of group D that eventually
survived were 0, 0, 0.33 and 0.
Mean ± SE concentrations of clarithromycin of group B at
3.5 και 24 hours were 5.44 ± 1.63 and 1.70 ± 0.59 µg/ml
respectively. Respective concentrations of group D were
4.77 ± 0.86 and 2.17 ± 0.86 µg/ml (pNS compared to
group B). Mean ± SE concentrations of amikacin of group
C at 3.5 and 24 hours were 6.12 ± 1.69 and 0.39 ± 0.19
µg/ml respectively. Respective concentrations of group D
were 7.68 ± 3.73 and 2.40 ± 1.50 µg/ml (pNS compared
to group B).
Discussion
Although immunomodulatory intervention is a very
attractive approach for the management of severe sepsis,
clinical attempts have failed. It is very probable that the
design of animal studies before the initiation of these
immunomodulators in clinical practice might be inade-
quate since in all animal models therapy is administered
before induction of sepsis [1]. The present study focused
on the application of clarithromycin as an immunomod-
ulator upon presentation of signs of urosepsis by multid-
rug-resistant  P. aeruginosa. Clarithromycin was
administered intravenously in order to achieve serum lev-
els close to 5 or 10 µg/ml; these concentrations are pro-
posed as adequate for the inhibition of biosynthesis of
pro-inflammatory cytokines by monocytes [4]. Amikacin
was co-administered to simulate the clinical state of noso-
comial sepsis often caused by multidrug-resistant species
and where antimicrobials probably inactive on the
offending pathogens are prescribed.
The advent of urosepsis was profound at the selected time
interval of therapy, as evidenced by hypothermia,
decrease of oxygen saturation and leucopenia (Figure 1).
Administration of clarithromycin was accompanied by an
increase of both rectal temperature and oxygen saturation
and by prolonged survival (Figures 1 and 2). Amikacin did
not have any effect neither on survival nor on the physical
signs of animals. Co-administration of clarithromycin
and amikacin allowed, however, for prolongation of sur-
vival to reach statistical significance.
The mode of action of clarithromycin might involve either
a direct effect on the test isolate or its intervention on the
inflammatory cascade. It has already been reported in ani-
mal models of chronic infection of the respiratory tract by
P. aeruginosa, that clarithomycin administered before
induction of the infection inhibited bacterial growth [12].
In vitro synergy with antipseudomonal β-lactams has also
been described [13]. However, in the present study a
direct effect of clarithromycin on the test isolate was
unlikely since no effect was noted either on the number of
bacteria in blood or in tissues (Table 3).
All groups of treatment were presented with the same
extent of bacteremia and endotoxemia (Table 1) and thus
with the same chance of triggering the inflammatory cas-
cade. Administration of clarithromycin effectuated
decrease of total oxidant status. That effect was attested by
serum levels of MDA in animals of group B as well as by
the area under the MDA curve in animals of group D.
These findings are consistent with in vitro reports on the
inhibition of neutrophil oxidative burst by clarithromycin
[14].
In order to discriminate the mode of action of clarithro-
mycin, blood monocytes were isolated from all animal
groups and assayed both for rate of apoptosis and ex vivo
release of TNFα (Table 2). Administration of clarithromy-
cin either single or in combination with amikacin effected
decrease of TNFα release by monocytes. In animals treated
by single amikacin, a pro-apoptotic effect was noted at 48
Table 3: Comparative bacterial load and pathology scores of tissues between groups of treatment of animals that died after bacterial 
challenge.
A (controls) B (clarithromycin) C (amikacin) D (clarithromycin + 
amikacin)
Bacterial load (mean ± SE, log10 of cfu/mL)
Liver 3.46 ± 0.79 3.34 ± 0.89 4.19 ± 0.92 2.14 ± 0.59
Spleen 3.64 ± 0.75 3.63 ± 0.92 4.10 ± 0.90 3.58 ± 0.79
Kidney 5.94 ± 0.50 4.92 ± 0.73 6.63 ± 0.30 6.82 ± 0.12
Lung 4.73 ± 0.59 4.09 ± 0.83 6.28 ± 0.39 5.76 ± 0.62
Pathology score (mean ± SE)
Liver 1.25 ± 0.25 0.38 ± 0.18a 0.80 ± 0.20 0.71 ± 0.28
Spleen 2.50 ± 0.38 2.70 ± 0.37 2.80 ± 0.20 2.43 ± 0.37
Kidney 2.38 ± 0.46 2.13 ± 0.52 2.30 ± 0.58 2.71 ± 0.36
Lung 1.38 ± 0.32 0.75 ± 0.25b 1.30 ± 0.16 1.29 ± 0.29
P of comparisons to group A: a0.012, b0.049BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
Page 8 of 10
(page number not for citation purposes)
hours. On the contrary, therapy by both clarithromycin
and amikacin induced decrease of the total caspase-3
activity of monocytes. All these observations are consist-
ent with a beneficiary effect of clarithromycin on the biol-
ogy of blood monocytes.
The correlation between the presence of bacteria in organs
and the respective pathology scores might be applied as
an indirect criterion for the anti-inflammatory mode of
action of clarithromycin. It is evident from Table 3 that
bacteria in spleen and lung were not affected after the sin-
gle administration of clarithromycin though their pathol-
ogy score was decreased. Spleen is a major lymphoid
organ where the presence of bacteria always stimulates an
intense inflammatory reaction. The absence of such a
reaction despite the presence of the offending pathogen,
which is further indicated by the negative correlation
between bacterial load and pathology scoring, is consist-
ent with an anti-inflammatory mode of action of clari-
thromycin. (Figure 3 and Table 3).
Single clarithromycin exerted a per se immunomodula-
tory mode of action as evidenced by its beneficiary effect
on vital signs and on the pathology scores of liver and
spleen. Co-administration of clarithromycin and ami-
kacin prolonged survival of septic animals and decreased
(legend to color Figure) Figure 3
(legend to color Figure). (a) Section of lung with intense peribronchial inflammation of one animal of group A-controls that died 
1.5 days after bacterial challenge and; (b) showing very mild interstitial inflammation of one animal of group B-administered 
clarithromycin that died 2 days after bacterial challenge. (c) Section of spleen with intense activation of B- and T-lymphocyte 
dependent areas of one animal of group A-controls that died 3 days after bacterial challenge and; (d) showing moderate activa-
tion of these areas of one animal of group B-administered clarithromycin that died 3.5 days after bacterial challenge.BMC Infectious Diseases 2006, 6:31 http://www.biomedcentral.com/1471-2334/6/31
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blood oxidant status and monocyte apoptosis. The latter
findings might be consistent with a synergistic immu-
nomodulatory effect of both drugs.
Conclusion
The present study clearly showed that clarithromycin
administered intravenously upon advent of clinical signs
of experimental sepsis by multidrug-resistant P. aeruginosa
prolonged survival and ameliorated clinical findings. Its
effect was most probably attributed to immunomodula-
tory intervention on blood monocytes. The successful
results of this experimental study might be attributed to
the altered pharmacokinetic regimen of clarithromycin
allowing for serum levels higher than those achieved by
the conventional oral doses. Once daily slow release oral
formulations of clarithromycin deliver drug concentra-
tions in the epithelial lining fluid of lung similar to those
desired in the present study [15]. Further research should
also target to intravenous administration of clarithromy-
cin in order to elucidate the clinical significance of the
reported experimental results for patients with sepsis.
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